在复杂的皮肤冠状动脉干预后进行即时治疗的无阿司匹林策略
Ko Yamamoto1, Masahiro Natsuaki2, Hirotoshi Watanabe3
1Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
JACC. Cardiovascular interventions
|May 15, 2024
概括
与标准双抗血小板治疗 (DAPT) 相比,无阿司匹林策略在经历复杂皮肤冠状动脉干预 (PCI) 的患者中,在出血或心血管事件中没有显著差异. 这一发现支持无阿司匹林的DAPT作为复杂PCI患者的安全替代品.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于复杂的穿皮冠状动脉干预 (PCI) 无阿司匹林策略的研究有限.
- 在这个患者群体中,评估无阿司匹林方法的有效性和安全性至关重要.
研究的目的:
- 在接受复杂PCI的患者中,评估无阿司匹林策略与标准双抗血小板治疗 (DAPT) 的有效性和安全性.
- 为了确定阿司匹林的停止是否会影响该特定人群的重大出血或心血管事件.
主要方法:
- 从STOPDAPT-3试验进行了亚组分析,重点是复杂的PCI患者.
- 复杂的PCI被定义为包括多个血管,支架,病变,长支架长度或慢性完全闭塞在内的标准.
- 患者接受了低剂量普拉苏格勒单疗法 (无阿司匹林) 或低剂量普拉苏格勒和阿司匹林的DAPT.
主要成果:
- 在复杂的PCI患者中,与DAPT相比,无阿司匹林策略在严重出血中没有显著差异 (5.30%对3.70%).
- 在复杂的PCI患者中,无阿司匹林和DAPT组之间的心血管事件也没有显著差异 (5.78%和5.93%).
- 复杂和非复杂的PCI组之间没有观察到出血或心血管结局的显著相互作用.
结论:
- 在接受复杂PCI的患者中,无阿司匹林策略与标准DAPT在心血管事件和严重出血方面是可比的.
- 这些发现表明,对于复杂的PCI患者,可以考虑一种无阿司匹林的方法.
- 该研究没有发现无论PCI复杂性如何,结果都没有显著差异.
相关概念视频
01:26Peptic Ulcer Disease IV: Management
89
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
89
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
686
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
686
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
493
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
493
01:16Antianginal Drugs: Nitrates and β-Blockers
575
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
575